CTSH — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1227603	0.51	5/20
SCHEMBL192070	0.42	5/20
SCHEMBL191969	0.40	5/20
SCHEMBL25562	0.36	5/20
SCHEMBL24199	0.35	4/20
SCHEMBL1911353	0.33	4/20
Potassium Ion (SCHEMBL392020)	0.33	4/20
SCHEMBL3324591	0.62	3/20
SCHEMBL1899034	0.33	3/20
SCHEMBL24144	0.33	3/20
SCHEMBL1903005	0.32	3/20
SCHEMBL3347831	1.00	2/20
SCHEMBL3350907	1.00	2/20
SCHEMBL3353019	1.00	2/20
SCHEMBL4245502	1.00	2/20
SCHEMBL2310591	0.79	2/20
SCHEMBL2310594	0.79	2/20
SCHEMBL2310597	0.79	2/20
SCHEMBL4994654	0.79	2/20
SCHEMBL3346407	0.78	2/20

Clinical trials — most relevant to CTSH by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Thrombolysis in Factor Xa-inhibitors Trial	PHASE3	RECRUITING
Efficacy of Cerebrolysin Treatment as an add-on Therapy to Mechanical Thrombectomy in Acute Ischemic Stroke.	PHASE3	UNKNOWN
Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial	PHASE3	UNKNOWN
Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction	PHASE2	COMPLETED
Collagenase Total Occlusion-1 Trial	PHASE1	COMPLETED
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy	PHASE1	NOT_YET_RECRUITING
Turkish Adaptation of the CTS-6 Evaluation Tool: A Validation and Reliability Study	nan	NOT_YET_RECRUITING
A Cohort Study of Correlation Between Mast Cells and Prognosis in Patients With Acute Myocardial Infarction	nan	UNKNOWN
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis	nan	COMPLETED
Hematological Markers in Idiopathic Carpal Tunnel Syndrome	nan	COMPLETED
Multimodal Approach of Electrotherapy Versus Nerve Flossing Technique in Patient With Carpal Tunnel Syndrome	nan	UNKNOWN
Magnetic Nanoparticles System in Acute Coronary Syndrome	nan	COMPLETED
Time Course of Circulating Myocardial Biomarkers After a TASH Procedure.	nan	UNKNOWN
Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD	nan	NOT_YET_RECRUITING
Premature Coronary Artery Disease - Clinical and Molecular Genetic Aspects	nan	UNKNOWN
Remote Ischaemic Postconditioning in the Clinical Setting of NSTEACS and Urgent PCI	nan	COMPLETED
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS	nan	COMPLETED
The Viability-Guided Angioplasty After Acute Myocardial Infarction-Trial (The VIAMI-Trial)	nan	UNKNOWN
Pilot Study on the Effect of Intracoronary Cryotherapy on Stabilization of Vulnerable Plaque at Risk of Rupture	nan	WITHDRAWN
Hydrodissection Between Normal Saline and a Combination of Triamcinolone Acetonide, Normal Saline, and Lidocaine in CTS	nan	COMPLETED
Modified HEART as Rule Out for Suspected ACS	nan	UNKNOWN
Double Kissing-crush vs Controlled Balloon-crush Techniques For Complex Coronary Bfurcation Lesions	nan	RECRUITING
Exploring the MEchanism of Plaque Rupture in Acute Coronary Syndrome Using Coronary CT Angiography and computationaL Fluid Dynamic	nan	UNKNOWN
Intraneural Facilitation as a Treatment for Carpal Tunnel Syndrome	nan	COMPLETED
Assessment of Disease Severity, Progression and Treatment in Infected Patients Presenting to the Emergency Department	nan	COMPLETED
Comparison of Clinical Efficacy of Submucosal Dexamethasone and Oral Trypsin-chymotrypsin for Reduction of Postoperative Sequelae After Lower Third Molar Surgery	nan	RECRUITING
Physical Therapy in Carpal Tunnel Syndrome	nan	COMPLETED
Circulating Markers for Ischemic Heart Disease	nan	RECRUITING
Effect of Exercise on Ultrasound SWV in CTS Patients	nan	COMPLETED
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CTSH binder may also engage these)

Protein	Name	Similarity
P49935	—	1.000	P49935 →
O46427	—	1.000	O46427 →
Q3T0I2	—	1.000	Q3T0I2 →
P00786	—	1.000	P00786 →
O70370	—	0.998	O70370 →
Q91ZF2	—	0.996	Q91ZF2 →
P25326	—	0.995	P25326 →
Q9JI81	—	0.995	Q9JI81 →
Q8RWQ9	—	0.994	Q8RWQ9 →
A0A072UTP9	—	0.994	A0A072UTP9 →
Q80UB0	—	0.993	Q80UB0 →
P55097	—	0.993	P55097 →
Q02765	—	0.993	Q02765 →
Q5E968	—	0.993	Q5E968 →
D3ZZ07	—	0.992	D3ZZ07 →
Q3ZKN1	—	0.992	Q3ZKN1 →
Q9JL96	—	0.992	Q9JL96 →
Q63088	—	0.992	Q63088 →
Q9QZE3	—	0.992	Q9QZE3 →
P06797	—	0.992	P06797 →
Q9TST1	—	0.992	Q9TST1 →
A0A068CNX1	—	0.992	A0A068CNX1 →
P15242	—	0.991	P15242 →
Q9JIA9	—	0.991	Q9JIA9 →
Q9R013	—	0.990	Q9R013 →
Q8VYS0	—	0.989	Q8VYS0 →
O35186	—	0.989	O35186 →
CTSS	Cathepsin S	0.989	landscape →
P25773	—	0.989	P25773 →
P56203	—	0.988	P56203 →